title: Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease.
abstract: Recent advances in clinical molecular and genetic studies on Alzheimer's disease (AD) are summarized here. Cerebrospinal fluid (CSF) Aβ42 and tau are the most sensitive biomarkers for the diagnosis of AD and prediction of its onset following mild cognitive impairment (MCI). Based on this progress, new diagnostic criteria for AD dementia, MCI due to AD, and preclinical AD were proposed by the National Institute of Aging (NIA) and Alzheimer's Association (AA) in April 2011. In these new criteria, progress in CSF biomarker and amyloid imaging studies over the past 10 years has added to critical information. The marked contributions of basic and clinical studies have established clinical evidence supporting these markers. Based on this progress, essential curative therapy for AD is urgently expected.
authors.affiliation: Department of Neurology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, Aomori 036-8216, Japan. mshoji@cc.hirosaki-u.ac.jp
authors.forename: Mikio
authors.initials: M
authors.lastname: Shoji
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D000818:Animals; D015415:Biomarkers / Q000134:cerebrospinal fluid; D006801:Humans; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D016875:tau Proteins